| 臺大學術典藏 |
2022-09-19T03:17:19Z |
Prevention and monitoring of hepatotoxicity among patients receiving antituberculosis medications
|
FEI-YUAN HSIAO; Yen Y.-H.; Lee C.-N.; Huang W.-F.; Chen H.-Y. |
| 臺大學術典藏 |
2022-09-15T01:09:01Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
Lee J.-H.; Chen T.W.-W.; Hsu C.-H.; Yen Y.-H.; Yang J.C.-H.; Cheng A.-L.; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; Chia-Chi Lin |
| 臺大學術典藏 |
2022-09-07T06:50:29Z |
Sex differences in conscious sedation during upper gastrointestinal panendoscopic examination
|
Yen Y.-H.; Lin T.-F.; Lin C.-J.; YI-CHIA LEE; Lau H.-P.; Yeh H.-M. |
| 臺大學術典藏 |
2022-04-21T06:50:39Z |
A polymorphism in interferon L3 Is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis c virus infection
|
Chang K.-C.; Tseng P.-L.; Wu Y.-Y.; Hung H.-C.; Huang C.-M.; Lu S.-N.; Wang J.-H.; Lee C.-M.; Chen C.-H.; Tsai M.-C.; Yen Y.-H.; Lin M.-T.; Wu C.-K.; Huang C.-C.; Chen, Tony Hsiu Hsi; Hu T.-H. |
| 臺大學術典藏 |
2022-04-15T06:39:21Z |
Intensive care unit-acquired weakness
|
Siao S.-F.; Yen Y.-H.; Yu Y.-F.; Zong S.-L.; CHERYL CHIA-HUI CHEN |
| 臺大學術典藏 |
2022-03-15T05:39:21Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
Lee J.-H.; WEI-WU CHEN; Hsu C.-H.; Yen Y.-H.; Yang J.C.-H.; Cheng A.-L.; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; Lin C.-C. |
| 臺大學術典藏 |
2022-03-09T03:12:42Z |
Serum and endometrial markers
|
Yang W.-C.V.; HUEI-WEN CHEN; Au H.-K.; Chang C.-W.; Huang C.-T.; Yen Y.-H.; Tzeng C.-R. |
| 臺大學術典藏 |
2022-02-23T02:12:21Z |
Chronic hepatitis B exhibited higher rate of hepatocellular carcinoma occurrence than hepatitis C in cirrhotic patients after effective antiviral treatment
|
Lin M.-T.; Chang K.-C.; Yen Y.-H.; Tsai M.-C.; CHIEN-HUNG CHEN; Wang J.-H.; Hsiao C.-C.; Chiu Y.-H.; Hu T.-H. |
| 臺大學術典藏 |
2022-02-23T02:12:18Z |
Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis (Front. Oncol., (2021), 11, (737767), 10.3389/fonc.2021.737767)
|
Kuo Y.-H.; Lu S.-N.; Chen Y.-Y.; Kee K.-M.; Yen Y.-H.; Hung C.-H.; Hu T.-H.; CHIEN-HUNG CHEN; Wang J.-H. |
| 臺大學術典藏 |
2022-02-23T02:12:18Z |
Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
|
Kuo Y.-H.; Lu S.-N.; Chen Y.-Y.; Kee K.-M.; Yen Y.-H.; Hung C.-H.; Hu T.-H.; CHIEN-HUNG CHEN; Wang J.-H. |
| 臺大學術典藏 |
2022-02-22T05:34:11Z |
Chronic hepatitis B exhibited higher rate of hepatocellular carcinoma occurrence than hepatitis C in cirrhotic patients after effective antiviral treatment
|
Lin M.-T.; Chang K.-C.; Yen Y.-H.; Tsai M.-C.; CHIEN-HUNG CHEN; Wang J.-H.; Hsiao C.-C.; Chiu Y.-H.; Hu T.-H. |
| 臺大學術典藏 |
2022-02-22T05:34:08Z |
Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
|
Kuo Y.-H.; Lu S.-N.; Chen Y.-Y.; Kee K.-M.; Yen Y.-H.; Hung C.-H.; Hu T.-H.; CHIEN-HUNG CHEN; Wang J.-H. |
| 臺大學術典藏 |
2022-02-22T05:34:07Z |
Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis (Front. Oncol., (2021), 11, (737767), 10.3389/fonc.2021.737767)
|
Kuo Y.-H.; Lu S.-N.; Chen Y.-Y.; Kee K.-M.; Yen Y.-H.; Hung C.-H.; Hu T.-H.; CHIEN-HUNG CHEN; Wang J.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:32Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
JIH-HSIANG LEE; Chen T.W.-W.; Hsu C.-H.; Yen Y.-H.; Yang J.C.-H.; Cheng A.-L.; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; Lin C.-C. |
| 臺大學術典藏 |
2021-08-31T06:29:19Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
Lee J.-H.; Chen T.W.-W.; Hsu C.-H.; Yen Y.-H.; Yang J.C.-H.; ANN-LII CHENG; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; Lin C.-C. |
| 臺大學術典藏 |
2021-07-13T06:04:29Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
LEE JIH-HSIANG; Chen T.W.-W.; Hsu C.-H.; Yen Y.-H.; Yang J.C.-H.; Cheng A.-L.; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; Lin C.-C. |
| 臺大學術典藏 |
2021-03-18T03:23:30Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
Lee J.-H.; WEI-WU CHEN; Hsu C.-H.; Yen Y.-H.; Yang J.C.-H.; Cheng A.-L.; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; Lin C.-C. |
| 臺大學術典藏 |
2021-02-02T05:45:33Z |
Sex differences in conscious sedation during upper gastrointestinal panendoscopic examination
|
Yen Y.-H.; Lin T.-F.; Lin C.-J.; YI-CHIA LEE; Lau H.-P.; Yeh H.-M. |
| 臺大學術典藏 |
2021 |
Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinoma
|
Tsai M.-C.; Hu T.-H.; Hsiao C.-C.; Yen Y.-H.; Yao C.-C.; YU-CHIEH TSAI; Chuang C.-H.; Lin C.-C.; Liu Y.-W.; Chen K.-D.; Wang C.-C.; Yang S.-Y. |
| 臺大學術典藏 |
2020-12-15T06:30:01Z |
Thalidomide inhibits fibronectin production in TGF-β1-treated normal and keloid fibroblasts via inhibition of the p38/Smad3 pathway
|
Liang C.-J.; Yen Y.-H.; Hung L.-Y.; Wang S.-H.; Pu C.-M.; Chien H.-F.; JAW-SHIUN TSAI; Lee C.-W.; Yen F.-L.; Chen Y.-L. |
| 臺大學術典藏 |
2020-11-26T07:48:17Z |
Intensive care unit-acquired weakness
|
Siao S.-F.;Yen Y.-H.;Yu Y.-F.;Zong S.-L.;Cheryl Chia-Hui Chen; Siao S.-F.; Yen Y.-H.; Yu Y.-F.; Zong S.-L.; CHERYL CHIA-HUI CHEN |
| 臺大學術典藏 |
2020-06-30T03:30:10Z |
Curcumin accelerates cutaneous wound healing via multiple biological actions: The involvement of TNF-α, MMP-9, α-SMA, and collagen
|
Yen Y.-H.;Pu C.-M.;Liu C.-W.;Chen Y.-C.;Chen Y.-C.;Liang C.-J.;Jung-Hsien Hsieh;Huang H.-F.;Chen Y.-L.; Yen Y.-H.; Pu C.-M.; Liu C.-W.; Chen Y.-C.; Chen Y.-C.; Liang C.-J.; JUNG-HSIEN HSIEH; Huang H.-F.; Chen Y.-L. |
| 臺大學術典藏 |
2020-05-26T09:26:16Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
Lee J.-H; Chen T.W.-W; Hsu C.-H; Yen Y.-H; CHIH-HSIN YANG; Cheng A.-L; Sasaki S.-I; Chiu L.Y; Sugihara M; Ishizuka T; Oguma T; Tajima N; Lin C.-C.; Lee J.-H;Chen T.W.-W;Hsu C.-H;Yen Y.-H;Chih-Hsin Yang;Cheng A.-L;Sasaki S.-I;Chiu L.Y;Sugihara M;Ishizuka T;Oguma T;Tajima N;Lin C.-C. |
| 臺大學術典藏 |
2020-05-25T07:35:01Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
Chia-Chi Lin;Tajima N;Oguma T;Ishizuka T;Sugihara M;Chiu L.Y;Sasaki S.-I;Cheng A.-L;Yang J.C.-H;Yen Y.-H;Hsu C.-H;Chen T.W.-W;Lee J.-H; Lee J.-H; Chen T.W.-W; Hsu C.-H; Yen Y.-H; Yang J.C.-H; Cheng A.-L; Sasaki S.-I; Chiu L.Y; Sugihara M; Ishizuka T; Oguma T; Tajima N; Chia-Chi Lin |
| 臺大學術典藏 |
2020-04-28T07:25:08Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
Lee J.-H.; Lee J.-H.;Chen T.W.-W.;Chih-Hung Hsu;Yen Y.-H.;Yang J.C.-H.;Cheng A.-L.;Sasaki S.-I.;Chiu L.Y.;Sugihara M.;Ishizuka T.;Oguma T.;Tajima N.;Lin C.-C.; Chen T.W.-W.; CHIH-HUNG HSU; Yen Y.-H.; Yang J.C.-H.; Cheng A.-L.; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; Lin C.-C. |
